**KEEP BEATS & BURDENS OF AFIB IN BALANCE**

MULTAQ® COMBINES AN EFFICACY AND SAFETY PROFILE TO MAINTAIN SINUS RHYTHM LONGER AND REDUCE CV HOSPITALIZATIONS

- **NO TITRATION FOR RENAL IMPAIRMENT**
  - Check cardiac rhythm at least once every 3 months
  - Monitor renal function periodically

- **NO CONTINUOUS ECG MONITORING REQUIREMENT**

- **NO IN-HOSPITAL INITIATION REQUIRED**

**INDICATION**
MULTAQ® is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AFib) in patients in sinus rhythm with a history of paroxysmal or persistent AFib.

**IMPORTANT SAFETY INFORMATION** for MULTAQ (dronedarone)

**WARNING:** INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION

MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure. MULTAQ doubles the risk of death in these patients.

MULTAQ is contraindicated in patients in atrial fibrillation (AFib) who will not or cannot be cardioverted into normal sinus rhythm. In patients with permanent AFib, MULTAQ doubles the risk of death, stroke, and hospitalization for heart failure.

*Please see additional Important Safety Information, including monitoring considerations and boxed WARNING, on pages 5-7. For full Prescribing Information, click [here](#) or visit [MULTAQ.com/hcp](http://MULTAQ.com/hcp).
In patients with paroxysmal or persistent AFib

**Efficacy and Safety Were Evaluated in a Wide Range of Patients**\(^2,3\)

<table>
<thead>
<tr>
<th>Typical AFib Patients* (EURIDIS/ADONIS study; N=1237)(^1,2)</th>
<th>Afib Patients With Defined Additional Risk Factors† (ATHENA study; N=4628)(^1,3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>57% Hypertension</td>
<td>86%</td>
</tr>
<tr>
<td>42% Structural Heart Disease</td>
<td>60%</td>
</tr>
<tr>
<td>22% Coronary Artery Disease</td>
<td>30%</td>
</tr>
<tr>
<td>17% CHF (NYHA CLASS I/II)</td>
<td>29% HISTORY OF CHF (CLASS I to III)</td>
</tr>
</tbody>
</table>

\*Forms of structural heart disease observed in patients on the EURIDIS/ADONIS trial include valvular disease (16%), nonischemic cardiomyopathy (6%), and hypertrophic cardiomyopathy (3%). Other CV history included implanted pacemaker (7%), rheumatic heart disease (3%), implanted cardioverter/defibrillator (1%), and congenital heart disease (1%).

\†Forms of structural heart disease observed in patients on the ATHENA trial include valvular disease (16%) and nonischemic cardiomyopathy (6%). Other CV history included LVEF <45% (12%) and LVEF <35% (4%).

MULTAQ® IS CONTRAINDICATED IN PATIENTS WITH NYHA CLASS IV HEART FAILURE OR SYMPTOMATIC HEART FAILURE WITH RECENT DECOMPENSATION REQUIRING HOSPITALIZATION.\(^1\)

Please see additional Important Safety Information, including boxed WARNING, on pages 5-7. For full Prescribing Information, click [here](#) or visit MULTAQ.com/hcp.

**IMPORTANT SAFETY INFORMATION**

**MULTAQ is also contraindicated in patients:**
- With second- or third-degree atrioventricular (AV) block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker), bradycardia <50 bpm, QTc Bazett interval ≥500 ms or PR interval >280 ms
- Who are or may become pregnant (Category X) or nursing. MULTAQ may cause fetal harm when administered to a pregnant woman
- With concomitant use of strong CYP 3A inhibitors, such as ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, ritonavir, or drugs or herbal products that prolong the QT interval and might increase the risk of Torsade de Pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics.
In patients with paroxysmal or persistent AFib

MULTAQ® DEMONSTRATED EFFICACY ACROSS MULTIPLE MEASURES¹,²

THE AFib RECURRENCE STUDY (EURIDIS/ADONIS) data* showed²:

- **25% RRR in 1st AFib recurrence** \( (P<0.001) \) with patients remaining in sinus rhythm **2.2x longer**
  - The absolute difference in rate of 1st recurrence at Year 1 for MULTAQ vs placebo was 11%.
  - The median time in sinus rhythm for MULTAQ patients was 116 days vs 53 days for placebo.

- **NO RECURRENCE of symptomatic AFib** in **62.3%** of MULTAQ patients at Year 1 vs **54%** in placebo \( (P<0.001) \)

THE HOSPITALIZATION STUDY (ATHENA) data*,$ showed¹:

- **24% RRR of CV hospitalization or all-cause mortality** (combined endpoint), entirely attributable to reduction in CV hospitalization, vs placebo
  - MULTAQ reduced the relative risk of CV hospitalization or all-cause mortality by 24% \( (HR=0.76, 95\% \text{ CI}: 0.68-0.83; P<0.0001) \). Hospitalization/mortality rates were 31.6% with MULTAQ vs 39.2% with placebo.

- **39% RRR of AFib hospitalization** vs placebo
  - MULTAQ reduced the risk of AFib hospitalization by **39%** \( (HR=0.61, 95\% \text{ CI}: 0.53-0.71; P<0.0001) \). AFib hospitalization rates were 12.7% with MULTAQ vs 19.6% with placebo.

AFib hospitalization was a component of the CV hospitalization secondary endpoint \( (26\% \text{ RRR}, \text{ HR}=0.74; 95\% \text{ CI}: 0.67-0.82; P<0.0001) \). CV hospitalization rates were **29.1%** with MULTAQ vs **36.8%** with placebo.

---

*Pooled data from 2 identical, multicenter, randomized, double-blind, placebo-controlled, parallel-group trials (12 months; N=1237; n=828 in MULTAQ arms; n=409 in placebo arms). Primary endpoint was time to first symptomatic or asymptomatic recurrence of AFib/AFL. Secondary endpoint was incidence of symptomatic first AFib recurrence.

¹Symptomatic AFib recurrence included 1 or more of the following symptoms: palpitations, dizziness, fatigue, chest pain, and/or dyspnea.

²Median follow-up was 22 months; maximum follow-up was 30 months.

³Data from a prospective, randomized, placebo-controlled, double-blind, multinational, multicenter, parallel-group trial (30-month maximum duration; N=4628; n=2301 in MULTAQ arm; n=2327 in placebo arm). Primary endpoint was time to first CV hospitalization, or death from any cause (results entirely attributable to effect on CV hospitalization, principally related to AFib; P<0.0001). Secondary endpoints were CV hospitalization \( (P<0.0001) \) and all-cause mortality \( (P=NS) \).

Please see additional Important Safety Information, including boxed WARNING, on pages 5-7. For full Prescribing Information, click here or visit MULTAQ.com/hcp.

IMPORTANT SAFETY INFORMATION (cont’d)

MULTAQ is also contraindicated in patients:

- With liver or lung toxicity related to the previous use of amiodarone
- With severe hepatic impairment
- With hypersensitivity to the active substance or to any of the excipients

Cardiovascular Death in NYHA Class IV or Decompensated Heart Failure

MULTAQ is contraindicated in patients with NYHA Class IV heart failure or symptomatic heart failure with recent decompensation requiring hospitalization because it doubles the risk of death.
INITIATION AND MONITORING

For patients with paroxysmal or persistent AFib

features specific to MULTAQ®¹

✓ Out-of-hospital initiation
✓ No need for continuous ECG monitoring
✓ No need for loading dose or titration
✓ No dose titration for renal impairment
✓ No specific assessment of thyroid function required
✓ No warning or precaution in patients with CAD or structural heart disease

MONITORING CONSIDERATIONS

• Patients treated with MULTAQ should undergo monitoring of cardiac rhythm no less often than every 3 months
• Consider obtaining periodic hepatic serum enzymes, especially during first 6 months of treatment
• Monitor renal function periodically
• Monitor INR after initiating MULTAQ in patients taking warfarin

SAFETY AND TOLERABILITY PROFILE¹

• Most frequent adverse reactions (>2%) with MULTAQ vs placebo: diarrhea (9% vs 6%), nausea (5% vs 3%), abdominal pain (4% vs 3%), vomiting (2% vs 1%), asthenia (7% vs 5%), respectively
• Discontinuation rates were generally similar between MULTAQ and placebo (11.8% and 7.7%, respectively). The most common reasons were GI disorders (3.2%) and QT prolongation (1.5%)

CARD=coronary artery disease; GI=gastrointestinal; INR=international normalized ratio.

Please see additional Important Safety Information, including monitoring considerations and boxed WARNING, on pages 5-7.
For full Prescribing Information, click here or visit MULTAQ.com/hcp.

IMPORTANT SAFETY INFORMATION (cont’d)

Cardiovascular Death and Heart Failure in Permanent AFib
MULTAQ doubles the risk of cardiovascular death (largely arrhythmic) and heart failure events in patients with permanent AFib. Patients treated with MULTAQ should undergo monitoring of cardiac rhythm no less often than every 3 months. Cardiovert patients who are in AFib (if clinically indicated) or discontinue MULTAQ. MULTAQ offers no benefit in subjects in permanent AFib.

Increased Risk of Stroke in Permanent AFib
In a placebo-controlled study in patients with permanent AFib, dronedarone was associated with an increased risk of stroke, particularly in the first two weeks of therapy. MULTAQ should only be initiated in patients in sinus rhythm who are receiving appropriate antithrombotic therapy.
INDICATION
MULTAQ® is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AFib) in patients in sinus rhythm with a history of paroxysmal or persistent AFib.

IMPORTANT SAFETY INFORMATION for MULTAQ (dronedarone)

WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION

MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure. MULTAQ doubles the risk of death in these patients.

MULTAQ is contraindicated in patients in atrial fibrillation (AFib) who will not or cannot be cardioverted into normal sinus rhythm. In patients with permanent AFib, MULTAQ doubles the risk of death, stroke, and hospitalization for heart failure.

MULTAQ is also contraindicated in patients:
• With second- or third-degree atrioventricular (AV) block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker), bradycardia <50 bpm, QTc Bazett interval ≥500 ms or PR interval >280 ms
• Who are or may become pregnant (Category X) or nursing. MULTAQ may cause fetal harm when administered to a pregnant woman
• With concomitant use of strong CYP 3A inhibitors, such as ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, ritonavir, or drugs or herbal products that prolong the QT interval and might increase the risk of Torsade de Pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics
• With liver or lung toxicity related to the previous use of amiodarone
• With severe hepatic impairment
• With hypersensitivity to the active substance or to any of the excipients

Cardiovascular Death in NYHA Class IV or Decompensated Heart Failure
MULTAQ is contraindicated in patients with NYHA Class IV heart failure or symptomatic heart failure with recent decompensation requiring hospitalization because it doubles the risk of death.

Cardiovascular Death and Heart Failure in Permanent AFIb
MULTAQ doubles the risk of cardiovascular death (largely arrhythmic) and heart failure events in patients with permanent AFib. Patients treated with MULTAQ should undergo monitoring of cardiac rhythm no less often than every 3 months. Cardiovert patients who are in AFib (if clinically indicated) or discontinue MULTAQ. MULTAQ offers no benefit in subjects in permanent AFib.

Increased Risk of Stroke in Permanent AFIb
In a placebo-controlled study in patients with permanent AFib, dronedarone was associated with an increased risk of stroke, particularly in the first two weeks of therapy. MULTAQ should only be initiated in patients in sinus rhythm who are receiving appropriate antithrombotic therapy.
IMPORTANT SAFETY INFORMATION for MULTAQ (dronedarone) (cont’d)

New Onset or Worsening Heart Failure
New onset or worsening of heart failure has been reported during treatment with MULTAQ in the postmarketing setting. In a placebo-controlled study in patients with permanent AFib, increased rates of heart failure were observed in patients with normal left ventricular function and no history of symptomatic heart failure, as well as those with a history of heart failure or left ventricular dysfunction.

Advise patients to consult a physician if they develop signs or symptoms of heart failure, such as weight gain, dependent edema, or increasing shortness of breath. If heart failure develops or worsens and requires hospitalization, discontinue MULTAQ.

Liver Injury
Hepatocellular liver injury, including acute liver failure requiring transplant, has been reported in patients treated with MULTAQ in the postmarketing setting. Advise patients treated with MULTAQ to report immediately symptoms suggesting hepatic injury (such as anorexia, nausea, vomiting, fever, malaise, fatigue, right upper quadrant pain, jaundice, dark urine, or itching). Consider obtaining periodic hepatic serum enzymes, especially during the first 6 months of treatment. It is not known whether routine periodic monitoring of serum enzymes will prevent the development of severe liver injury. If hepatic injury is suspected, promptly discontinue MULTAQ and test serum enzymes, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase, as well as serum bilirubin, to establish whether there is liver injury. If liver injury is found, institute appropriate treatment and investigate the probable cause. Do not restart MULTAQ in patients without another explanation for the observed liver injury.

Pulmonary Toxicity
Cases of interstitial lung disease including pneumonitis and pulmonary fibrosis have been reported in patients treated with MULTAQ in the postmarketing setting. Onset of dyspnea or non-productive cough may be related to pulmonary toxicity and patients should be carefully evaluated clinically. If pulmonary toxicity is confirmed, MULTAQ should be discontinued.

Hypokalemia and Hypomagnesemia with Potassium-Depleting Diuretics
Hypokalemia and hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. Potassium levels should be within the normal range prior to administration of MULTAQ and maintained in the normal range during administration of MULTAQ.

QT Interval Prolongation
MULTAQ induces a moderate (average of about 10 ms but much greater effects have been observed) QTc (Bazett) prolongation. If the QTc Bazett interval is ≥500 ms, discontinue MULTAQ.

Renal Impairment and Failure
Marked increase in serum creatinine, pre-renal azotemia and acute renal failure, often in the setting of heart failure or hypovolemia, have been reported in patients taking MULTAQ. In most cases, these effects appear to be reversible upon drug discontinuation and with appropriate medical treatment. Monitor renal function periodically.

Small increases in creatinine levels (about 0.1 mg/dL) following MULTAQ treatment initiation have been shown to be a result of inhibition of creatinine’s tubular secretion. The elevation has a rapid onset, reaches a plateau after 7 days and is reversible after discontinuation.

Please see additional Important Safety Information, including boxed WARNING, on pages 5-7. For full Prescribing Information, click here or visit MULTAQ.com/hcp.
IMPORTANT SAFETY INFORMATION for MULTAQ (dronedarone) (cont’d)

Women of Childbearing Potential
Premenopausal women who have not undergone a hysterectomy or oophorectomy must use effective contraception while using MULTAQ. Dronedarone caused fetal harm in animal studies at doses equivalent to recommended human doses. Counsel women of childbearing potential regarding appropriate contraceptive choices.

Drug-Drug Interactions
• Treatment with Class I or III antiarrhythmics or drugs that are strong inhibitors of CYP 3A must be stopped before starting MULTAQ (see Contraindications)
• Patients should be instructed to avoid grapefruit juice beverages while taking MULTAQ
• Calcium channel blockers with depressant effects and beta-blockers could increase the bradycardia effects of MULTAQ on conduction
• In the ANDROMEDA (patients with recently decompensated heart failure) and PALLAS (patients with permanent AFib) trials, baseline use of digoxin was associated with an increased risk of arrhythmic or sudden death in MULTAQ-treated patients compared to placebo. In patients not taking digoxin, no difference in risk of sudden death was observed in the MULTAQ vs placebo groups
  
  Digoxin can potentiate the electrophysiologic effects of MULTAQ (such as decreased AV-node conduction). MULTAQ increases exposure to digoxin.
  
  Consider discontinuing digoxin. If digoxin treatment is continued, halve the dose of digoxin, monitor serum levels closely, and observe for toxicity
• Postmarketing cases of increased INR with or without bleeding events have been reported in warfarin-treated patients initiated with MULTAQ. Monitor INR after initiating MULTAQ in patients taking warfarin
• Statins: Avoid simvastatin doses greater than 10 mg daily. Follow statin label recommendations for use with CYP 3A and P-gp inhibitors such as MULTAQ

Adverse Reactions
In studies, the most common adverse reactions observed with MULTAQ were diarrhea, nausea, abdominal pain, vomiting, and asthenia.

MULTAQ has the HIGHEST AHA/ACC/HRS GUIDELINE RECOMMENDATION (CLASS 1, LEVEL A) as a 1st-line therapy for maintenance of sinus rhythm, based on extensive clinical trial evidence and real-world experience.

MULTAQ is the ONLY AAD STUDIED IN MULTIPLE, LARGE CLINICAL TRIALS enrolling nearly 6000 paroxysmal and persistent AFib patients.

AAD=antiarrhythmic drug; ACC=American College of Cardiology; AHA=American Heart Association; HRS=Heart Rhythm Society.

INDICATION
MULTAQ® is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AFib) in patients in sinus rhythm with a history of paroxysmal or persistent AFib.

IMPORTANT SAFETY INFORMATION for MULTAQ (dronedarone)

WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION
MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure. MULTAQ doubles the risk of death in these patients.
MULTAQ is contraindicated in patients in atrial fibrillation (AFib) who will not or cannot be cardioverted into normal sinus rhythm. In patients with permanent AFib, MULTAQ doubles the risk of death, stroke, and hospitalization for heart failure.